WO1999058116A3 - Novel formulation containing paroxetine - Google Patents

Novel formulation containing paroxetine Download PDF

Info

Publication number
WO1999058116A3
WO1999058116A3 PCT/GB1999/001522 GB9901522W WO9958116A3 WO 1999058116 A3 WO1999058116 A3 WO 1999058116A3 GB 9901522 W GB9901522 W GB 9901522W WO 9958116 A3 WO9958116 A3 WO 9958116A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulation containing
novel formulation
containing paroxetine
paroxetine
hemihydrate
Prior art date
Application number
PCT/GB1999/001522
Other languages
French (fr)
Other versions
WO1999058116A2 (en
Inventor
David Philip Elder
Graham Stanley Leonard
Original Assignee
Smithkline Beecham Plc
David Philip Elder
Graham Stanley Leonard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP99922303A priority Critical patent/EP1077685A2/en
Priority to EA200001173A priority patent/EA200001173A1/en
Application filed by Smithkline Beecham Plc, David Philip Elder, Graham Stanley Leonard filed Critical Smithkline Beecham Plc
Priority to PL99344872A priority patent/PL344872A1/en
Priority to IL13959699A priority patent/IL139596A0/en
Priority to AU39410/99A priority patent/AU3941099A/en
Priority to CA002331849A priority patent/CA2331849A1/en
Priority to KR1020007012660A priority patent/KR20010043545A/en
Priority to HU0101931A priority patent/HUP0101931A3/en
Priority to SK1697-2000A priority patent/SK16972000A3/en
Priority to BR9910402-4A priority patent/BR9910402A/en
Priority to APAP/P/2000/001985A priority patent/AP2000001985A0/en
Priority to JP2000547967A priority patent/JP2002514593A/en
Publication of WO1999058116A2 publication Critical patent/WO1999058116A2/en
Publication of WO1999058116A3 publication Critical patent/WO1999058116A3/en
Priority to NO20005681A priority patent/NO20005681L/en
Priority to BG105011A priority patent/BG105011A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Paroxetine hydrochloride, in a form other than the hemihydrate, which is formulated into capsules under conditions such there is no detectable conversion to hemihydrate during the manufacturing process.
PCT/GB1999/001522 1998-05-13 1999-05-13 Novel formulation containing paroxetine WO1999058116A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
SK1697-2000A SK16972000A3 (en) 1998-05-13 1999-05-13 Novel formulation containing paroxetine
HU0101931A HUP0101931A3 (en) 1998-05-13 1999-05-13 Novel formulation containing paroxetine
PL99344872A PL344872A1 (en) 1998-05-13 1999-05-13 Novel formulation containing paroxetine
EA200001173A EA200001173A1 (en) 1998-05-13 1999-05-13 NEW COMPOSITION CONTAINING PAROXETINE
AU39410/99A AU3941099A (en) 1998-05-13 1999-05-13 Novel formulation containing paroxetine
CA002331849A CA2331849A1 (en) 1998-05-13 1999-05-13 Novel formulation containing paroxetine
BR9910402-4A BR9910402A (en) 1998-05-13 1999-05-13 New formulation containing paroxetine
EP99922303A EP1077685A2 (en) 1998-05-13 1999-05-13 Novel formulation containing paroxetine
IL13959699A IL139596A0 (en) 1998-05-13 1999-05-13 Novel formulation containing paroxetine
KR1020007012660A KR20010043545A (en) 1998-05-13 1999-05-13 Novel Formulation Containing Paroxetine
APAP/P/2000/001985A AP2000001985A0 (en) 1998-05-13 1999-05-13 Novel formulation containing paroxetine.
JP2000547967A JP2002514593A (en) 1998-05-13 1999-05-13 Formulations containing new paroxetine
NO20005681A NO20005681L (en) 1998-05-13 2000-11-10 New formulations containing paroxetine
BG105011A BG105011A (en) 1998-05-13 2000-11-30 Composition containing paroxetine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9810180.1 1998-05-13
GBGB9810180.1A GB9810180D0 (en) 1998-05-13 1998-05-13 Novel formulation

Publications (2)

Publication Number Publication Date
WO1999058116A2 WO1999058116A2 (en) 1999-11-18
WO1999058116A3 true WO1999058116A3 (en) 2000-02-17

Family

ID=10831926

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/001522 WO1999058116A2 (en) 1998-05-13 1999-05-13 Novel formulation containing paroxetine

Country Status (20)

Country Link
EP (1) EP1077685A2 (en)
JP (1) JP2002514593A (en)
KR (1) KR20010043545A (en)
CN (1) CN1309557A (en)
AP (1) AP2000001985A0 (en)
AU (1) AU3941099A (en)
BG (1) BG105011A (en)
BR (1) BR9910402A (en)
CA (1) CA2331849A1 (en)
EA (1) EA200001173A1 (en)
GB (1) GB9810180D0 (en)
HU (1) HUP0101931A3 (en)
ID (1) ID27018A (en)
IL (1) IL139596A0 (en)
NO (1) NO20005681L (en)
PL (1) PL344872A1 (en)
SK (1) SK16972000A3 (en)
TR (1) TR200003351T2 (en)
WO (1) WO1999058116A2 (en)
ZA (1) ZA200006465B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE50011819D1 (en) 1999-03-12 2006-01-12 Aesica Pharmaceuticals Ltd STABLE PHARMACEUTICAL APPLICATION FOR PAROXETIN ANHYDRATE
HU226912B1 (en) * 2000-04-07 2010-03-01 Richter Gedeon Nyrt New paroxetin salt and medicament containing it
JP6062422B2 (en) * 2012-03-29 2017-01-18 杏林製薬株式会社 Capsule formulation
DE102013207447A1 (en) 2013-04-24 2014-10-30 Evonik Degussa Gmbh Process and apparatus for the preparation of octachlorotrisilane
CN103520131B (en) * 2013-10-12 2019-05-14 浙江华海药业股份有限公司 The preparation method of paroxetine hydrochloride semihydrate capsule
CN103961333B (en) * 2014-05-07 2020-02-21 浙江华海药业股份有限公司 Paroxetine mesylate capsule and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031197A1 (en) * 1995-04-03 1996-10-10 Abbott Laboratories Homogeneous mixtures of low temperature-melting drugs and additives for controlled release
WO1999026625A1 (en) * 1997-11-21 1999-06-03 Smithkline Beecham Plc Formulations comprising dissolved paroxetine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031197A1 (en) * 1995-04-03 1996-10-10 Abbott Laboratories Homogeneous mixtures of low temperature-melting drugs and additives for controlled release
WO1999026625A1 (en) * 1997-11-21 1999-06-03 Smithkline Beecham Plc Formulations comprising dissolved paroxetine

Also Published As

Publication number Publication date
BG105011A (en) 2001-07-31
ID27018A (en) 2001-02-22
CN1309557A (en) 2001-08-22
NO20005681L (en) 2000-12-01
TR200003351T2 (en) 2001-03-21
GB9810180D0 (en) 1998-07-08
JP2002514593A (en) 2002-05-21
WO1999058116A2 (en) 1999-11-18
ZA200006465B (en) 2001-11-09
KR20010043545A (en) 2001-05-25
HUP0101931A2 (en) 2002-04-29
HUP0101931A3 (en) 2002-10-28
EP1077685A2 (en) 2001-02-28
IL139596A0 (en) 2002-02-10
AU3941099A (en) 1999-11-29
NO20005681D0 (en) 2000-11-10
SK16972000A3 (en) 2001-06-11
CA2331849A1 (en) 1999-11-18
BR9910402A (en) 2001-01-09
PL344872A1 (en) 2001-11-19
AP2000001985A0 (en) 2000-12-31
EA200001173A1 (en) 2001-04-23

Similar Documents

Publication Publication Date Title
AU2001234999A1 (en) A process for forming a semiconductor structure
WO2001047928A3 (en) Imidazo 1,3,5 triazinones and the use thereof
HK1042698B (en) New diphenylurea compounds, a process for their preparation and pharmaceutical compositions containing them
HK1039117B (en) New piperidine-4-sulphonamide compounds, a process for their preparation and pharmaceutical compositions containing them
WO1999058116A3 (en) Novel formulation containing paroxetine
WO2000046210A3 (en) New process for preparing pesticidal intermediates
HUP0104272A3 (en) New cyclobutendione compounds, a process for their preparation and pharmaceutical compositions containing them
ZA99477B (en) Process for the preparation of (-)CIS-3-Hydroxy-1-Methyl-4-(2,4,6-Trimethoxyphenyl)Piperidine.
WO2002072567A3 (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
WO1999058113A3 (en) Novel formulation containing paroxetine
HUP0000308A2 (en) New cyano-indole serotonin-reuptake inhibitor compounds, a process for their preparation and pharmaceutical compositions containing them
CA2370956A1 (en) Method for causticisation of alkaline solutions
AU2002229648A1 (en) A process for the preparation of citalopram
HK1047101A1 (en) Bicyclic amino-pyrazinone compounds, a process fortheir preparation and pharmaceutical compositions containing them.
WO2001029032A8 (en) Process for the preparation of paroxetine
AU9437698A (en) Compressed chloramine-t tablets and method for the production thereof
AU6870600A (en) Process for the preparation of 2,3-dihydroazepine compounds
AU7773900A (en) Novel c13-substituted estra-1,3,5(10)-triene-3-yl-sulfamates, a method for producing the same and pharmaceutical compositions containing these compounds
HK1051845A1 (en) Substituted 1 and 2 naphthol mannich bases
AU2566100A (en) Process for the production of a nutritional composition
CA2366600A1 (en) A process for the preparation of 1,4,7,10-tetraazacyclododecane
IL137364A0 (en) A process for the preparation of 6,6-dimethylhept-1-en-4-yn-3-ol
AU2002223617A1 (en) Novel neurokinin antagonists, method for the production thereof and pharmaceutical compositions containing said compounds
HUP0401989A3 (en) A process for the preparation of the 14 beta-hydroxy-baccatin iii-1,14-carbonate
EP1186588A4 (en) 6-hydroxy-2-naphthylcarbinol and process for the preparation thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99808548.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 508036

Country of ref document: NZ

Ref document number: 39410/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999922303

Country of ref document: EP

Ref document number: 2000/06465

Country of ref document: ZA

Ref document number: 139596

Country of ref document: IL

Ref document number: 16972000

Country of ref document: SK

Ref document number: 200006465

Country of ref document: ZA

Ref document number: 09700267

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2331849

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PV2000-4185

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1020007012660

Country of ref document: KR

Ref document number: PA/a/2000/011153

Country of ref document: MX

Ref document number: 2000/03351

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 200001173

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1999922303

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2000-4185

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020007012660

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1999922303

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2000-4185

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1020007012660

Country of ref document: KR